Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A possible association between primary aldosteronism and a lower beta-cell function.

Lorena M Mosso1, Cristian A Carvajal, Alberto Maiz

  • 1Department of Nutrition and Diabetes, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.

Journal of Hypertension
|September 22, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Low-renin hypertension in incidental adrenal adenomas and response to aldosterone-targeted therapy: a prospective study.

European journal of internal medicine·2026
Same author

Case Report: Conventional therapy versus volanesorsen in two sisters with familial chylomicronemia syndrome.

Frontiers in nutrition·2026
Same author

Adipocyte extracellular vesicles (AdEVs) promote a proinflammatory and profibrotic profile in human renal and endothelial cells in vitro.

International journal of obesity (2005)·2026
Same author

Driving hypertension: non-classic apparent mineralocorticoid excess.

Nature reviews. Endocrinology·2025
Same author

Primary Aldosteronism in a Hispanic Cohort: Responses to Mineralocorticoid Receptor Antagonism and Remission in a Case.

American journal of hypertension·2025
Same author

Influence of estradiol deficiency on the mineralocorticoid receptor response in postmenopausal women: a cross-sectional study.

Climacteric : the journal of the International Menopause Society·2025

Primary aldosteronism (PA) is linked to impaired glucose metabolism due to lower beta-cell function, not insulin resistance. Aldosterone significantly impacts glucose regulation in PA patients.

Area of Science:

  • Endocrinology
  • Metabolic Disorders
  • Hypertension Research

Background:

  • Primary aldosteronism (PA) is the most common secondary cause of hypertension.
  • PA has been recently implicated in impaired glucose tolerance.
  • The specific effects of PA on glucose metabolism, insulin sensitivity, and insulin secretion require further investigation.

Purpose of the Study:

  • To investigate glucose metabolism, insulin sensitivity, and insulin secretion in patients with idiopathic PA.
  • To compare these parameters between PA patients and essential hypertensive (EH) patients.
  • To evaluate the effects of spironolactone treatment on glucose metabolism in PA patients.

Main Methods:

  • A comparative study included 30 PA patients and 60 EH patients, matched for BMI, age, and gender.

Related Experiment Videos

  • Measurements included fasting glucose, insulin, C-peptide, total cholesterol, and triglycerides.
  • Insulin resistance (HOMA-IR) and beta-cell function (HOMA-betaF) were calculated. Spironolactone's effect was assessed in 19 PA patients.

    • Main Results:

    • PA patients exhibited higher fasting glucose levels compared to EH patients.
    • Insulin levels and HOMA-IR were similar between groups, suggesting no difference in insulin resistance.
    • PA patients showed lower HOMA-betaF index and C-peptide levels, indicating reduced beta-cell function. Spironolactone increased C-peptide and insulin but did not alter HOMA-IR or HOMA-betaF.

    Conclusions:

    • PA patients demonstrate distinct glucose metabolism alterations, characterized by reduced beta-cell function, potentially influenced by aldosterone.
    • These findings underscore the significant role of aldosterone in regulating glucose metabolism.
    • Targeting aldosterone may be crucial for managing glucose metabolism disturbances in PA.